Global Hemostasis Diagnostics

Hemostasis Diagnostics Comprehensive Study by Type (Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems), Point-of-Care Testing Systems), Application (Hospital/Clinics, Independent Diagnostic Laboratories, Home Care Settings, Others), End Users (Adults, Kids), Test Type (Activated Partial Thromboplastin Time, D Dimer Test, Fibrinogen Test, Prothrombin Time (PT) Test, Others) Players and Region - Global Market Outlook to 2030

Hemostasis Diagnostics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hemostasis Diagnostics
When functioning correctly, hemostasis is a complex relationship between vessels, platelets, and coagulation proteins that slows bleeding by maintaining blood flow in the vessel. Hemostasis diagnostics are devices that help doctors treat patients that have bleeding disorders or blood clotting problems. According to sources, about 400,000 individuals worldwide have hemophilia, with 56 percent being undiagnosed. In 2019, approximately 20,000 Americans had hemophilia The ever-increasing need for medical technology advances will drive the demand for the market in the forecast period

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.1%


The competitive landscape of the hemostasis diagnostics market is constantly evolving, as companies strive to develop new and innovative products and technologies. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc. (United States), Instrumentation Laboratory (United States), F. Hoffmann-La Roche Ltd (Switzerland), Beckman Coulter Inc (United States), Nihon Kohden Corporation (Japan) and Grifols, S.A. (Spain) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sysmex Corporation (Japan), Siemens Healthineers (United States) and Alere Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Hemostasis Diagnostics market by Type (Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems) and Point-of-Care Testing Systems), Application (Hospital/Clinics, Independent Diagnostic Laboratories, Home Care Settings and Others) and Region.



On the basis of geography, the market of Hemostasis Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Adults will boost the Hemostasis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test Type, the sub-segment i.e. Activated Partial Thromboplastin Time will boost the Hemostasis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Adoption Of Automated Hemostasis Equipment

Market Growth Drivers:
Global Hemostasis Diagnostics Market Drivers: Impact Analysis, Increased Prevalence Of Hemostasis Diseases and Growing Healthcare Expenditure And Developing Healthcare Facilities

Challenges:
Lack Of Awareness In Developing Countries

Restraints:
High Cost Of Advanced Hemostasis Products

Opportunities:
High Spending On R&D and Adoption Of New Technologies

Market Leaders and their expansionary development strategies
On April 25, 2022: Acquired Phadia. Thermo Fisher Scientific Announces Completion of Acquisition of Phadia, Thermo Fisher Scientific announced the completion of its acquisition of Phadia. This information aligns with the previous query about Hemostasis Diagnostics
On January 10, 2023, Werfen Merged with Instrumentation Laboratory. Werfen merges with Instrumentation Laboratory. This involved a branding change, not a merger. Werfen continued to operate as a single entity after this date.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Hemostasis Diagnostics Providers, Venture Capitalists, Private Equity Firms, Government Regulatory, Research Organizations and End Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems)
  • Point-of-Care Testing Systems
By Application
  • Hospital/Clinics
  • Independent Diagnostic Laboratories
  • Home Care Settings
  • Others
By End Users
  • Adults
  • Kids

By Test Type
  • Activated Partial Thromboplastin Time
  • D Dimer Test
  • Fibrinogen Test
  • Prothrombin Time (PT) Test
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Hemostasis Diagnostics Market Drivers: Impact Analysis
      • 3.2.2. Increased Prevalence Of Hemostasis Diseases
      • 3.2.3. Growing Healthcare Expenditure And Developing Healthcare Facilities
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Awareness In Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption Of Automated Hemostasis Equipment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemostasis Diagnostics, by Type, Application, End Users, Test Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hemostasis Diagnostics (Value)
      • 5.2.1. Global Hemostasis Diagnostics by: Type (Value)
        • 5.2.1.1. Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems)
        • 5.2.1.2. Point-of-Care Testing Systems
      • 5.2.2. Global Hemostasis Diagnostics by: Application (Value)
        • 5.2.2.1. Hospital/Clinics
        • 5.2.2.2. Independent Diagnostic Laboratories
        • 5.2.2.3. Home Care Settings
        • 5.2.2.4. Others
      • 5.2.3. Global Hemostasis Diagnostics by: End Users (Value)
        • 5.2.3.1. Adults
        • 5.2.3.2. Kids
      • 5.2.4. Global Hemostasis Diagnostics by: Test Type (Value)
        • 5.2.4.1. Activated Partial Thromboplastin Time
        • 5.2.4.2. D Dimer Test
        • 5.2.4.3. Fibrinogen Test
        • 5.2.4.4. Prothrombin Time (PT) Test
        • 5.2.4.5. Others
      • 5.2.5. Global Hemostasis Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hemostasis Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sysmex Corporation (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Instrumentation Laboratory (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Beckman Coulter Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nihon Kohden Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Grifols, S.A. (Spain)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Hemostasis Diagnostics Sale, by Type, Application, End Users, Test Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hemostasis Diagnostics (Value)
      • 7.2.1. Global Hemostasis Diagnostics by: Type (Value)
        • 7.2.1.1. Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems)
        • 7.2.1.2. Point-of-Care Testing Systems
      • 7.2.2. Global Hemostasis Diagnostics by: Application (Value)
        • 7.2.2.1. Hospital/Clinics
        • 7.2.2.2. Independent Diagnostic Laboratories
        • 7.2.2.3. Home Care Settings
        • 7.2.2.4. Others
      • 7.2.3. Global Hemostasis Diagnostics by: End Users (Value)
        • 7.2.3.1. Adults
        • 7.2.3.2. Kids
      • 7.2.4. Global Hemostasis Diagnostics by: Test Type (Value)
        • 7.2.4.1. Activated Partial Thromboplastin Time
        • 7.2.4.2. D Dimer Test
        • 7.2.4.3. Fibrinogen Test
        • 7.2.4.4. Prothrombin Time (PT) Test
        • 7.2.4.5. Others
      • 7.2.5. Global Hemostasis Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemostasis Diagnostics: by Type(USD Million)
  • Table 2. Hemostasis Diagnostics Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems) , by Region USD Million (2018-2023)
  • Table 3. Hemostasis Diagnostics Point-of-Care Testing Systems , by Region USD Million (2018-2023)
  • Table 4. Hemostasis Diagnostics: by Application(USD Million)
  • Table 5. Hemostasis Diagnostics Hospital/Clinics , by Region USD Million (2018-2023)
  • Table 6. Hemostasis Diagnostics Independent Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 7. Hemostasis Diagnostics Home Care Settings , by Region USD Million (2018-2023)
  • Table 8. Hemostasis Diagnostics Others , by Region USD Million (2018-2023)
  • Table 9. Hemostasis Diagnostics: by End Users(USD Million)
  • Table 10. Hemostasis Diagnostics Adults , by Region USD Million (2018-2023)
  • Table 11. Hemostasis Diagnostics Kids , by Region USD Million (2018-2023)
  • Table 12. Hemostasis Diagnostics: by Test Type(USD Million)
  • Table 13. Hemostasis Diagnostics Activated Partial Thromboplastin Time , by Region USD Million (2018-2023)
  • Table 14. Hemostasis Diagnostics D Dimer Test , by Region USD Million (2018-2023)
  • Table 15. Hemostasis Diagnostics Fibrinogen Test , by Region USD Million (2018-2023)
  • Table 16. Hemostasis Diagnostics Prothrombin Time (PT) Test , by Region USD Million (2018-2023)
  • Table 17. Hemostasis Diagnostics Others , by Region USD Million (2018-2023)
  • Table 18. South America Hemostasis Diagnostics, by Country USD Million (2018-2023)
  • Table 19. South America Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 20. South America Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 21. South America Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 22. South America Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 23. Brazil Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 24. Brazil Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 25. Brazil Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 26. Brazil Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 27. Argentina Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 28. Argentina Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 29. Argentina Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 30. Argentina Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 31. Rest of South America Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 34. Rest of South America Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 35. Asia Pacific Hemostasis Diagnostics, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 39. Asia Pacific Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 40. China Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 41. China Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 42. China Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 43. China Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 44. Japan Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 45. Japan Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 46. Japan Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 47. Japan Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 48. India Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 49. India Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 50. India Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 51. India Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 52. South Korea Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 53. South Korea Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 54. South Korea Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 55. South Korea Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 56. Taiwan Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 57. Taiwan Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 58. Taiwan Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 59. Taiwan Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 60. Australia Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 61. Australia Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 62. Australia Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 63. Australia Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 68. Europe Hemostasis Diagnostics, by Country USD Million (2018-2023)
  • Table 69. Europe Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 70. Europe Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 71. Europe Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 72. Europe Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 73. Germany Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 74. Germany Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 75. Germany Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 76. Germany Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 77. France Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 78. France Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 79. France Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 80. France Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 81. Italy Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 82. Italy Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 83. Italy Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 84. Italy Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 85. United Kingdom Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 88. United Kingdom Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 89. Netherlands Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 90. Netherlands Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 91. Netherlands Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 92. Netherlands Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 93. Rest of Europe Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 96. Rest of Europe Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 97. MEA Hemostasis Diagnostics, by Country USD Million (2018-2023)
  • Table 98. MEA Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 99. MEA Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 100. MEA Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 101. MEA Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 102. Middle East Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 103. Middle East Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 104. Middle East Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 105. Middle East Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 106. Africa Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 107. Africa Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 108. Africa Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 109. Africa Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 110. North America Hemostasis Diagnostics, by Country USD Million (2018-2023)
  • Table 111. North America Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 112. North America Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 113. North America Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 114. North America Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 115. United States Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 116. United States Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 117. United States Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 118. United States Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 119. Canada Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 120. Canada Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 121. Canada Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 122. Canada Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 123. Mexico Hemostasis Diagnostics, by Type USD Million (2018-2023)
  • Table 124. Mexico Hemostasis Diagnostics, by Application USD Million (2018-2023)
  • Table 125. Mexico Hemostasis Diagnostics, by End Users USD Million (2018-2023)
  • Table 126. Mexico Hemostasis Diagnostics, by Test Type USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Hemostasis Diagnostics: by Type(USD Million)
  • Table 136. Hemostasis Diagnostics Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems) , by Region USD Million (2025-2030)
  • Table 137. Hemostasis Diagnostics Point-of-Care Testing Systems , by Region USD Million (2025-2030)
  • Table 138. Hemostasis Diagnostics: by Application(USD Million)
  • Table 139. Hemostasis Diagnostics Hospital/Clinics , by Region USD Million (2025-2030)
  • Table 140. Hemostasis Diagnostics Independent Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 141. Hemostasis Diagnostics Home Care Settings , by Region USD Million (2025-2030)
  • Table 142. Hemostasis Diagnostics Others , by Region USD Million (2025-2030)
  • Table 143. Hemostasis Diagnostics: by End Users(USD Million)
  • Table 144. Hemostasis Diagnostics Adults , by Region USD Million (2025-2030)
  • Table 145. Hemostasis Diagnostics Kids , by Region USD Million (2025-2030)
  • Table 146. Hemostasis Diagnostics: by Test Type(USD Million)
  • Table 147. Hemostasis Diagnostics Activated Partial Thromboplastin Time , by Region USD Million (2025-2030)
  • Table 148. Hemostasis Diagnostics D Dimer Test , by Region USD Million (2025-2030)
  • Table 149. Hemostasis Diagnostics Fibrinogen Test , by Region USD Million (2025-2030)
  • Table 150. Hemostasis Diagnostics Prothrombin Time (PT) Test , by Region USD Million (2025-2030)
  • Table 151. Hemostasis Diagnostics Others , by Region USD Million (2025-2030)
  • Table 152. South America Hemostasis Diagnostics, by Country USD Million (2025-2030)
  • Table 153. South America Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 154. South America Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 155. South America Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 156. South America Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 157. Brazil Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 158. Brazil Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 159. Brazil Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 160. Brazil Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 161. Argentina Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 162. Argentina Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 163. Argentina Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 164. Argentina Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 165. Rest of South America Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 167. Rest of South America Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 168. Rest of South America Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 169. Asia Pacific Hemostasis Diagnostics, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 171. Asia Pacific Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 172. Asia Pacific Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 173. Asia Pacific Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 174. China Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 175. China Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 176. China Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 177. China Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 178. Japan Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 179. Japan Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 180. Japan Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 181. Japan Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 182. India Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 183. India Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 184. India Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 185. India Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 186. South Korea Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 187. South Korea Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 188. South Korea Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 189. South Korea Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 190. Taiwan Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 191. Taiwan Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 192. Taiwan Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 193. Taiwan Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 194. Australia Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 195. Australia Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 196. Australia Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 197. Australia Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 202. Europe Hemostasis Diagnostics, by Country USD Million (2025-2030)
  • Table 203. Europe Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 204. Europe Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 205. Europe Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 206. Europe Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 207. Germany Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 208. Germany Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 209. Germany Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 210. Germany Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 211. France Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 212. France Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 213. France Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 214. France Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 215. Italy Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 216. Italy Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 217. Italy Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 218. Italy Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 219. United Kingdom Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 220. United Kingdom Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 221. United Kingdom Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 222. United Kingdom Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 223. Netherlands Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 224. Netherlands Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 225. Netherlands Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 226. Netherlands Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 227. Rest of Europe Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 228. Rest of Europe Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 229. Rest of Europe Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 230. Rest of Europe Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 231. MEA Hemostasis Diagnostics, by Country USD Million (2025-2030)
  • Table 232. MEA Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 233. MEA Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 234. MEA Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 235. MEA Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 236. Middle East Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 237. Middle East Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 238. Middle East Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 239. Middle East Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 240. Africa Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 241. Africa Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 242. Africa Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 243. Africa Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 244. North America Hemostasis Diagnostics, by Country USD Million (2025-2030)
  • Table 245. North America Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 246. North America Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 247. North America Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 248. North America Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 249. United States Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 250. United States Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 251. United States Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 252. United States Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 253. Canada Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 254. Canada Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 255. Canada Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 256. Canada Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 257. Mexico Hemostasis Diagnostics, by Type USD Million (2025-2030)
  • Table 258. Mexico Hemostasis Diagnostics, by Application USD Million (2025-2030)
  • Table 259. Mexico Hemostasis Diagnostics, by End Users USD Million (2025-2030)
  • Table 260. Mexico Hemostasis Diagnostics, by Test Type USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemostasis Diagnostics: by Type USD Million (2018-2023)
  • Figure 5. Global Hemostasis Diagnostics: by Application USD Million (2018-2023)
  • Figure 6. Global Hemostasis Diagnostics: by End Users USD Million (2018-2023)
  • Figure 7. Global Hemostasis Diagnostics: by Test Type USD Million (2018-2023)
  • Figure 8. South America Hemostasis Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Hemostasis Diagnostics Share (%), by Country
  • Figure 10. Europe Hemostasis Diagnostics Share (%), by Country
  • Figure 11. MEA Hemostasis Diagnostics Share (%), by Country
  • Figure 12. North America Hemostasis Diagnostics Share (%), by Country
  • Figure 13. Global Hemostasis Diagnostics share by Players 2023 (%)
  • Figure 14. Global Hemostasis Diagnostics share by Players (Top 3) 2023(%)
  • Figure 15. Global Hemostasis Diagnostics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 19. Sysmex Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Sysmex Corporation (Japan) Revenue: by Geography 2023
  • Figure 21. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Instrumentation Laboratory (United States) Revenue, Net Income and Gross profit
  • Figure 24. Instrumentation Laboratory (United States) Revenue: by Geography 2023
  • Figure 25. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 27. Beckman Coulter Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. Beckman Coulter Inc (United States) Revenue: by Geography 2023
  • Figure 29. Nihon Kohden Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Nihon Kohden Corporation (Japan) Revenue: by Geography 2023
  • Figure 31. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 32. Grifols, S.A. (Spain) Revenue: by Geography 2023
  • Figure 33. Global Hemostasis Diagnostics: by Type USD Million (2025-2030)
  • Figure 34. Global Hemostasis Diagnostics: by Application USD Million (2025-2030)
  • Figure 35. Global Hemostasis Diagnostics: by End Users USD Million (2025-2030)
  • Figure 36. Global Hemostasis Diagnostics: by Test Type USD Million (2025-2030)
  • Figure 37. South America Hemostasis Diagnostics Share (%), by Country
  • Figure 38. Asia Pacific Hemostasis Diagnostics Share (%), by Country
  • Figure 39. Europe Hemostasis Diagnostics Share (%), by Country
  • Figure 40. MEA Hemostasis Diagnostics Share (%), by Country
  • Figure 41. North America Hemostasis Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Sysmex Corporation (Japan)
  • Thermo Fisher Scientific, Inc. (United States)
  • Instrumentation Laboratory (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Beckman Coulter Inc (United States)
  • Nihon Kohden Corporation (Japan)
  • Grifols, S.A. (Spain)
Additional players considered in the study are as follows:
Sysmex Corporation (Japan) , Siemens Healthineers (United States) , Alere Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 244 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hemostasis Diagnostics Quantitative research analysis
Global Hemostasis Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc. (United States), Instrumentation Laboratory (United States), F. Hoffmann-La Roche Ltd (Switzerland), Beckman Coulter Inc (United States), Nihon Kohden Corporation (Japan) and Grifols, S.A. (Spain) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Adoption Of Automated Hemostasis Equipment" is seen as one of major influencing trends for Hemostasis Diagnostics Market during projected period 2023-2030.
The Hemostasis Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hemostasis Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Genetic Modification Therapies Comprehensive Study by Type (Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies, Gene Editing), Application (Hospitals, Diagnostics and Testing Laborato...
$ 3450
Brain Tumor Therapeutics Comprehensive Study by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), Treatment Type (Surgery, Radiation Th...
$ 3650
Retinal Biologics Comprehensive Study by Application (Hospitals, Clinics, Research Organizations, Others), Diagnostic Tests (Amsler grid test, Optical coherence tomography (OCT), Fundus autofluoresce...
$ 3650
Enteric Empty Capsules Comprehensive Study by Type (Gelatin Capsules (Pig Meat Gelatin, Bovine-Derived Gelatin.Bone Meal, and Other Gelatin Sources), Non-Gelatin Capsules (Hydroxypropyl Methylcellulo...
$ 3750
Mouth Ulcer Treatment Drug Comprehensive Study by Route of Administration (Oral, Topical), Drugs Class (Corticosteroid, Analgesic, Antibiotic, Anti-Inflammatory, Others), Distribution Channel (Hospit...
$ 3800
Alopecia Treatment Comprehensive Study by Type (Topical Drugs (Creams, Oils, Gels, Shampoo, Lotions, Foams), Oral Drugs, Injectable Drugs (Platelet-rich Plasma. Injections, Injectable Fillers), Hair ...
$ 3750